Triple
T19157591
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | maftivimab |
E468964
|
entity |
| Predicate | hasMolecularTarget |
P37016
|
FINISHED |
| Object | Ebola virus glycoprotein |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ebola virus glycoprotein | Statement: [maftivimab, hasMolecularTarget, Ebola virus glycoprotein]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ebola virus glycoprotein Context triple: [maftivimab, hasMolecularTarget, Ebola virus glycoprotein]
-
A.
SARS-CoV-2 spike glycoprotein
The SARS-CoV-2 spike glycoprotein is the viral surface protein that mediates coronavirus entry into human cells and is the primary target of neutralizing antibodies and many COVID-19 vaccines.
-
B.
Taï Forest ebolavirus
Taï Forest ebolavirus is a rare species of ebolavirus known for causing a single documented non-fatal human infection linked to contact with infected chimpanzees in Côte d’Ivoire.
-
C.
Reston ebolavirus
Reston ebolavirus is a species of ebolavirus that primarily infects nonhuman primates and pigs and is notable for being the only known ebolavirus that has caused asymptomatic infections in humans.
-
D.
Ebolavirus
Ebolavirus is a genus of filamentous, enveloped RNA viruses in the Filoviridae family that cause severe and often fatal hemorrhagic fever in humans and other primates.
-
E.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ebola virus glycoprotein Target entity description: Ebola virus glycoprotein is the surface protein of the Ebola virus responsible for mediating host cell attachment and membrane fusion, and is a primary target for neutralizing antibodies and antiviral therapies.
-
A.
SARS-CoV-2 spike glycoprotein
The SARS-CoV-2 spike glycoprotein is the viral surface protein that mediates coronavirus entry into human cells and is the primary target of neutralizing antibodies and many COVID-19 vaccines.
-
B.
Taï Forest ebolavirus
Taï Forest ebolavirus is a rare species of ebolavirus known for causing a single documented non-fatal human infection linked to contact with infected chimpanzees in Côte d’Ivoire.
-
C.
Reston ebolavirus
Reston ebolavirus is a species of ebolavirus that primarily infects nonhuman primates and pigs and is notable for being the only known ebolavirus that has caused asymptomatic infections in humans.
-
D.
Ebolavirus
Ebolavirus is a genus of filamentous, enveloped RNA viruses in the Filoviridae family that cause severe and often fatal hemorrhagic fever in humans and other primates.
-
E.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd084ff48190ac0f8c46ee722629 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5eeba91a081909c04d61d6117da06 |
completed | April 20, 2026, 9:15 a.m. |
Created at: April 10, 2026, 12:06 p.m.